Primary M1 macrophages as multifunctional carrier combined with PLGA nanoparticle delivering anticancer drug for efficient glioma therapy
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Glioma remains difficult to treat because of the infiltrative growth of tumor cells and their resistance to standard therapy. Despite rapid development of targeted drug delivery system, the current therapeutic efficacy is still challenging. Based on our previous studies, macrophages have been proved to be promising drug carrier for active glioma delivery. To make full use of macrophage carrier, primary M1 macrophages were proposed to replace regular macrophage to deliver nanodrugs into glioma, because M1 macrophages not only have the natural ability to home into tumor tissues, but they also have stronger phagocytic capability than other types of macrophage, which can enable them to uptake enough drug-loaded nanoparticles for therapy. In addition, M1 macrophages are not easily affected by harsh tumor microenvironment and inhibit tumor growth themselves. In this study, M1 macrophage-loaded nanoparticles (M1-NPs) were prepared by incubating poly(lactide-co-glycolide) (PLGA) nanoparticles with primary M1 macrophages. In vitro cell assays demonstrated M1 macrophage still maintained good tumor tropism capability after particle loading, and could efficiently carry particles across endothelial barrier into tumor tissues. In vivo imaging verified that M1-NPs exhibited higher brain tumor distribution than free nanoparticles. DOX@M1-NPs (doxorubicin-loaded M1-NPs) presented significantly enhanced anti-glioma effect with prolonged survival median and increased cell apoptosis. In conclusion, the results provided a new strategy exploiting M1 macrophage as carrier for drug delivery, which improved targeting efficiency and therapeutic efficacy of chemodrugs for glioma therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The M1 and M2 paradigm of macrophage activation: Time for reassessment
Martinez, F. O., & Gordon, S. (2014) · F1000Prime Reports · doi:10.12703/p6-13 · Cited by 4,689 · cited 4×
“M1 macrophages can generate pro-inflammatory cytokines to help destroy foreign organisms and tumor cells (Kroner et al., 2014; Martinez & Gordon, 2014), induce T-helper-1-type cell response, and increase the production of interferon-gamma by both T and NK cells (Zhang et al., 2013; Cheema et al.,…”
BackgroundInfluentialTumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
How leukocytes cross the vascular endothelium
Vestweber, D. (2015) · Nature Reviews Immunology · doi:10.1038/nri3908 · Cited by 858 · cited 1×
“When tumor occurs, the cell adhesion molecules on the vascular endothelial cells are overexpressed due to inflammation environment, which facilitate the initial process of macrophage rolling, firm attachment to endothelium, and transmigration (Sutton et al., 2014; Vestweber 2015).”
BackgroundKroner, A., Greenhalgh, A. D., Zarruk, J. G., Passos dos Santos, R., Gaestel, M., & David, S. (2014) · Neuron · doi:10.1016/j.neuron.2014.07.027 · Cited by 655
Drug delivery to the central nervous system by polymeric nanoparticles: What do we know?
Kreuter, J. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.008 · Cited by 554
Shiraishi, K., Hamano, M., Ma, H., Kawano, K., Maitani, Y., Aoshi, T., Ishii, K. J., & Yokoyama, M. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.11.016 · Cited by 141 · cited 1×
“However, there are still many hurdles to overcome, including complicated fabrication process, high opsonization in the circulation, low tumor targeting ability, and frequently occurred immune responses against new materials(Shiraishi et al., 2013; Verhoef et al., 2014; Peng et al., 2016).”
BackgroundNano-engineered mesenchymal stem cells as targeted therapeutic carriers
Sadhukha, T., O'Brien, T. D., & Prabha, S. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.10.015 · Cited by 115 · cited 2×
“In vitro migration The tumor tropic ability of M1 or M1-NPs toward U87 tumor cells in vitro was examined by transwell migration test (Sadhukha et al., 2014; Fu et al., 2015).”
MethodMacrophages Offer A Paradigm Switch for CNS Delivery of Therapeutic Proteins
Klyachko, N. L., Haney, M. J., Zhao, Y., Manickam, D. S., Mahajan, V., Suresh, P., Hingtgen, S. D., Mosley, R. L., Gendelman, H. E., Kabanov, A. V., et al. (2014) · Nanomedicine · doi:10.2217/nnm.13.115 · Cited by 92
Wong, D., Prameya, R., & Dorovini-Zis, K. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.12.003 · Cited by 88
Cited by
Engineering Macrophages for Cancer Immunotherapy and Drug Delivery
Xia, Y., Rao, L., Yao, H., Wang, Z., Ning, P., & Chen, X. (2020) · Advanced Materials · doi:10.1002/adma.202002054 · Cited by 949
Wu, Y., Wan, S., Yang, S., Hu, H., Zhang, C., Lai, J., Zhou, J., Chen, W., Tang, X., Luo, J., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01746-6 · Cited by 301
Frontiers in the treatment of glioblastoma: Past, present and emerging
Janjua, T. I., Rewatkar, P., Ahmed-Cox, A., Saeed, I., Mansfeld, F. M., Kulshreshtha, R., Kumeria, T., Ziegler, D. S., Kavallaris, M., Mazzieri, R., et al. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.012 · Cited by 257
Recent Advances in Macrophage-Mediated Drug Delivery Systems
Liang, T., Zhang, R., Liu, X., Ding, Q., Wu, S., Li, C., Lin, Y., Ye, Y., Zhong, Z., & Zhou, M. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s298159 · Cited by 126
“An M1 macrophage-biomimetic drug delivery system was able to treat glioma, and its efficacy reflected the strong phagocytic ability and good drug loading characteristic of the M1 phenotype.(67) By exploiting the extracellular vehicles known as exosomes, which are secreted by nearly all cells and have specific surface…”
BackgroundWang, L., Shi, Y., Jiang, J., Li, C., Zhang, H., Zhang, X., Jiang, T., Wang, L., Wang, Y., & Feng, L. (2022) · Small · doi:10.1002/smll.202203678 · Cited by 71
Metadata
- Authors
- Pang, L., Zhu, Y., Qin, J., Zhao, W., & Wang, J.
- Venue
- Drug Delivery
- Publisher
- Informa UK Limited
- Published
- 2018-01-01
- Volume
- 25
- Issue
- 1
- Pages
- 1922-1931
- ISSN
- 1071-7544 (ISSN-L)
- 1521-0464
- OpenAlex
- W2901858923
- Cited by
- 129
- References
- 9
- FWCI
- 2.32
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Primary M1 macrophages as multifunctional carrier combined with PLGA nanoparticle delivering anticancer drug for efficient glioma therapy. https://app.cochat.ai/papers/10.1080/10717544.2018.1502839
- The paper
- Pang, L., Zhu, Y., Qin, J., Zhao, W., & Wang, J. (2018). Primary M1 macrophages as multifunctional carrier combined with PLGA nanoparticle delivering anticancer drug for efficient glioma therapy. Drug Delivery. https://doi.org/10.1080/10717544.2018.1502839
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.